Industry Outlook 2025: The Impact of Politics on Pharma

Industry Outlook 2025: The Impact of Politics on Pharma

The PharmTech Group interviewed Edwin Stone, CEO of Cellular Origins, about the impact of the changing political landscape on the pharmaceutical industry.

Key MEP on pharma legislation: Trump tariffs will 'impact' pharma package

Euractiv sat down with Nicolás González Casares, shadow rapporteur on the directive on medicinal products for human use, to take stock of the future of the Pharma package.

In Ireland, a global hub for the pharma industry, Trump tariffs are a source of deep worry

As the country braces for possible investment losses following any new levies, drugmakers see their own reasons for concern.

RUTH SUNDERLAND: Donald Trump's bitter pill for pharma could boost UK

Americans may end up paying more for their medicines as well as facing shortages of drugs they need. So it's possible there are glimmers of opportunity here.

The analysts of AlphaValue consider that all the noise caused by Donald Trump’s tariffs has created a good entry point in Swiss pharmaceutical Novartis. Abhishek Raval, his specialist in the pharmaceutical sector, has raised its target price from 98.2 to 102 Swiss francs, after raising its profit per share (BPA) to 2025 to 6.54 from 6.46 dollars and by 2026, and after cutting to 6.70 from 6.95 dollars in a note that headlines Focus exclusively o…

STAT+: In Ireland, A Global Hub For The Pharma Industry, Trump Tariffs Are A Source Of Deep Worry

The hulking factories are tucked away off the roads around the village of Ringaskiddy — operated by the likes of Pfizer, Johnson & Johnson, and BioMarin, whose plant featured signs last week touting a new facility “coming Q1 2027.” The nearby town of Carrigtwohill crows that it’s grown “+400% over the past 20 years,” a surge driven by sites run by GSK, AbbVie, and Gilead.  advertisement And down in Kinsale, an Eli Lilly campus rises up out of t…